Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Lenalidomide
Related studies linked through entity extraction aliases.
Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year
- Status
- COMPLETED
- Phase
- PHASE2
Selinexor and Backbone Treatments of Multiple Myeloma Patients
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)
- Status
- COMPLETED
- Phase
- PHASE3
Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE1
Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis
- Status
- TERMINATED
- Phase
- PHASE2
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
- Status
- TERMINATED
- Phase
- PHASE2
Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE3
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q)
- Status
- COMPLETED
- Phase
- N/A
E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan
- Status
- COMPLETED
- Phase
- PHASE2
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML
- Status
- TERMINATED
- Phase
- PHASE1
Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2